Tarsus announces positive topline Phase 2a results for TP-03 in MGD with Demodex mites

Tarsus Pharmaceuticals, Inc.

Ersa trial evaluated TP-03 (lotilaner ophthalmic solution, 0.25%) BID or TID for 12 weeks.
Trial enrolled Meibomian Gland Disease patients with Demodex mites.
Company states positive topline results; detailed data presented in corporate deck.
No specific efficacy or safety numbers disclosed in the 8-K filing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.